The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.

Autoimmune DiseaseSystemic Lupus Erythematosus

Elevated Semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.

Clin Exp Immunol.

Du Y, Wu X, Chen M, Wang W, Xv W, Ye L, Wu D, Xue J, Sun W, Luo J, Wu H

doi: 10.1111/cei.12924.

Systemic Lupus Erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

doi: 10.1136/annrheumdis-2018-214427.

Autoimmune DiseaseSystemic Lupus Erythematosus

Identification of potential biomarkers for systemic lupus erythematosus diagnosis using two-dimensional differential gel electrophoresis (2D-DIGE) and mass spectrometry

Autoimmunity.

Ferreira TAR, de Andrade HM, de Pádua PM, Carvalho MDG, Pires SDF, Oliveira IHR, Lima BSS, Fialho Júnior LC, Cicarini WB, Chapeourouge DA, Perales JH, Guimarães TMPD, Toledo VPCP

doi: 10.1080/

Systemic Lupus Erythematosus

High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth

Arthritis Care Res (Hoboken).

Chang JC, Mandell DS, Knight AM

doi: 10.1002/acr.23485.

Systemic Lupus Erythematosus

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Clin Neurol Neurosurg.

Carnero Contentti E, Genco ND, Hryb JP, Caspi M, Chiganer E, Di Pace JL, López PA, Lessa C, Caride A, Perassolo M

doi: 10.1016/

Systemic Lupus Erythematosus

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Lupus Sci Med.

Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, Vainshtein I, Farmer E, Rosenthal K, Morehouse C, de Los Reyes M, Schifferli K, Liang M, Sanjuan MA, Sims GP, Kolbeck R

doi: 10.1136/

Further Publications Rheumatology

Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Ann Rheum Dis

Jesus D, Larosa M, Henriques C, Matos A, Zen M, Tomé P, Alves V, Costa N, Le Guern V, Iaccarino L, Costedoat-Chalumeau N, Doria A, Inês LS

doi: 10.1136/annrheumdis-2021-220363

Autoimmune Disease

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lancet.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S

doi: 10.1016/S0140-

Systemic Lupus Erythematosus

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

J Rheumatol

Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH

doi: 10.3899/jrheum.200802

Related content

Elevated Semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Identification of potential biomarkers for systemic lupus erythematosus diagnosis using two-dimensional differential gel electrophoresis (2D-DIGE) and mass spectrometry

High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus